What is the fat-to-muscle loss ratio on retatrutide?

What Public Trial Data Show

Public Lilly topline releases for TRIUMPH-1 and TRIUMPH-4 report body-weight outcomes and waist-circumference outcomes, but they do not report a verified DEXA-derived fat-mass and lean-mass split for retatrutide. The 24.2% figure sometimes attached to Phase 3 body-composition claims is actually the 2023 New England Journal of Medicine Phase 2 obesity trial result at 12 mg over 48 weeks.

Because a public primary source for a TRIUMPH-1 fat-to-lean ratio is not available, specific claims that retatrutide produces a fixed 75% fat / 25% lean-mass loss ratio should not be treated as established.

What This Means Clinically

Any large weight-loss intervention can reduce both fat mass and lean mass. Retatrutide's glucagon receptor activity gives it a plausible fat-oxidation mechanism, but public Phase 3 topline data are not enough to quantify a precise fat-to-muscle loss ratio.

Retatrutide is still investigational. Body-composition expectations should be based on measured patient data, not assumed class averages or unsupported trial-substudy claims.

How to Monitor Body Composition

• Use DEXA, validated bioimpedance, or another consistent body-composition method when available
• Track waist circumference alongside scale weight
• Track strength, training performance, and functional capacity
• Review rapid or disproportionate lean-mass loss with a qualified clinician

How to Reduce Lean-Mass Loss Risk

• Prioritize adequate protein intake during appetite suppression
• Use progressive resistance training throughout weight loss
• Maintain sleep, recovery, and micronutrient adequacy
• Avoid pursuing unnecessarily rapid weight loss when lean mass preservation is a priority

Body Composition vs Scale Weight

Traditional weight-focused approach

• Scale weight as primary metric
• Doesn't distinguish fat vs lean
• May miss concerning lean mass loss

Body composition focused approach

• DEXA scans every 3–6 months
• InBody or similar BIA monthly
• Track waist circumference alongside weight
• Strength tracking in training

Signs of Excessive Muscle Loss

• Strength declining beyond 10% in compound lifts over 4 weeks
• Visible muscle "flattening" rather than "tightening"
• Significant decrease in waist-to-hip ratio exceeding expected (indicates not just fat loss)
• Fatigue that doesn't improve with weight loss
• Measurable grip strength decline

Interventions If Losing Too Much Muscle

• Increase protein intake
• Add additional resistance training session per week
• Slow weight loss rate
• Ensure adequate total calorie intake
• Consider adding creatine if not already using
• Evaluate for thyroid or hormonal contributions to excess muscle loss
• Maintain cardio at modest level rather than excessive

Bottom Line

A precise retatrutide fat-to-muscle loss ratio cannot be verified from public TRIUMPH-1 or TRIUMPH-4 topline data. Unsupported Phase 3 body-composition ratios should be discarded; the verified 24.2% figure is from the 2023 Phase 2 obesity trial. Use body-composition monitoring and lean-mass preservation basics rather than assuming a fixed ratio.

See the retatrutide guide. Related: trial results, dosage protocol.